TearScience, Inc. Lands $15 Million to Bring Novel Dry Eye Treatment to Market
10/4/2011 8:38:28 AM
Medical device company TearScience has secured $15 million in debt financing that the company will use to support a pair of products addressing evaporative dry eye. The venture debt financing comes from Oxford Finance and Silicon Valley Bank (NASDAQ:SIVB). To date, Morrisville, North Carolina-based TearScience has raised more than $70 million in venture capital financing since its 2005 founding. The company’s investors include Essex Woodlands Health Ventures, Investor Growth Capital, General Catalyst, De Novo Ventures, Spray Ventures and Quaker BioVentures.
comments powered by